BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 242.6 SEK | +7.35% |
|
+1.76% | -9.41% |
| May. 29 | Nordic Stocks Dropped Wednesday; NEL Fell Furthest | DJ |
| May. 27 | Nordic Shares Moved Upward Monday; Sinch Led Increases | DJ |
Presentation Operator MessageOperator (Operator)Welcome to BioArctic Q1 Report 2024. [Operator...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-08-29
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
242.6
SEK
Average target price
368
SEK
Spread / Average Target
+51.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.41% | 2.03B | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- BIOA B Stock
- News BioArctic AB
- Transcript : BioArctic AB, Q1 2024 Earnings Call, May 17, 2024
